TNGX · Tango Therapeutics, Inc.
$25.60
-0.05 (-0.19%)
At close · Aug 14
Market Cap
$4.32B
Shares
168.61M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$62.38M
+48.3%
FY2025
Net Income
-$101.59M
+22%
FY2025
Operating Margin
-178.39%
+167.7pp
FY2025
Diluted EPS
-$0.87
+26.9%
FY2025
Operating Cash Flow
-$138.89M
-5.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $53.81M | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | |
| $8.68M | $5.63M | $7.89M | $6.62M | $1.46M | $495K | $108K | |
| $133.65M | $132.17M | $143.92M | $115.2M | $105.91M | $77.64M | $49.99M | |
| $56.51M | $41.51M | $43.75M | $35.5M | $30.03M | $17.6M | $9.87M | |
| $190.16M | $173.67M | $187.66M | $150.7M | $135.93M | $95.23M | $59.86M | |
| -$136.35M | -$111.29M | -$145.6M | -$114.17M | -$111.07M | -$58.19M | -$52.2M | |
| — | -178.39% | -346.09% | -312.57% | -446.79% | -157.09% | -681.82% | |
| $12.56M | $9.7M | $15.5M | $12.56M | $2.95M | $247K | $228K | |
| -$123.78M | -$101.59M | -$130.09M | -$101.61M | -$108.12M | -$57.94M | -$51.97M | |
| -$63K | $4000 | $208K | $134K | $54K | $292K | $0 | |
| -$123.72M | -$101.59M | -$130.3M | -$101.74M | -$108.18M | -$58.24M | -$51.97M | |
| — | -162.85% | -309.73% | -278.54% | -435.14% | -157.21% | -678.84% | |
| -$124.45M | -$101.71M | -$130.15M | -$97.85M | -$111.12M | -$59.02M | -$51.97M | |
| USD/shares | — | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.94 | — |
| USD/shares | — | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.94 | — |
| shares | — | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M | 31.93M |
| shares | — | 116.17M | 109.23M | 94.57M | 87.82M | 62.11M | 31.93M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.46×
EV/EBIT
—
Peer median 27.68×
P/E (TTM)
—
Peer median 17.38×
Peer medians compare against the 211 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $62,384,000 | $29,969,000 | $31,527,000 | $24,860,000 | $26,042,000 | $6,972,000 |
| License Revenue | — | $12,100,000 | $5,000,000 | — | $11,000,000 | $684,000 |
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
245 filings
241 filers
Visit website
Investor relations